59 results on '"Hironaka S"'
Search Results
2. A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)
3. 1259TiP Investigator-initiated phase II study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability—high advanced gastric or esophagogastric junction cancer (NO LIMIT, WJOG13320G/CA209-7W7)
4. 389P Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)
5. 1488P A prognostic biomarker study in patients who underwent surgery or received chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma
6. 104P Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC)
7. Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT
8. A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study)
9. The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced esophageal cancer
10. Avelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial
11. Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G
12. Influence of Oral Anaerobic Bacteria on Hematopoietic Stem Cell Transplantation Patients: Oral Mucositis and General Condition
13. A clinical validation study of RASKET-B: A multiple detection kit for RAS and BRAF gene mutations in colorectal cancer
14. The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced small intestine cancer
15. A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies
16. Two year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab (ATTRACTION-01/ONO-4538-07)
17. CURRENT STATUS OF DENTAL INTERVENTION AND SAFETY MANAGEMENT IN THE DEMENTIA WARD
18. Examination of factors affecting the intraoral perception of object size: a preliminary study
19. Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study
20. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
21. 2301 Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538) in Patients with Esophageal Cancer: Preliminary Report
22. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
23. Evaluation of Sediment Transport Capacity Equations Using Basin Scale Process-Based Sediment Dynamic Modelling Approach
24. Impacts of Progression Type on Overall Survival in Advanced Gastric Cancer: Randomized Piii Study of S-1 + Oxaliplatin Vs. S-1 + Cisplatin
25. Clinical Validation of a Novel Multiplex Kit for All Ras Mutations in Colorectal Cancer: Results of Rasket(Ras Key Testing) Prospective Multicenter Study
26. Randomized Phase Ii Study of S-1 Plus Oral Leucovorin (Sl) Versus Sl Plus Oxaliplatin (Sol) Versus S-1 Plus Cisplatin (Sp) in Patients with Advanced Gastric Cancer (Agc):Updated Overall Survival Data
27. Rainbow: Global, Phase 3, Randomized, Double-Blind Study of Ramucirumab Plus Paclitaxel vs Placebo Plus Paclitaxel Patients with Previously Treated Gastric or Gastroesophageal Junction Adenocarcinoma – Patient-Reported Outcomes and Performance Status
28. Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer
29. Phase II Study of Concurrent Chemoradiotherapy at the Dose of 50.4 Gy with Elective Nodal Irradiation for Stage II-III Esophageal Carcinoma
30. Randomized Phase III Study of Irinotecan (CPT-11) Versus Weekly Paclitaxel (WPTX) for Advanced Gastric Cancer (AGC) Refractory to Combination Chemotherapy (CT) of Fluoropyrimidine Plus Platinum (FP): WJOG4007 Trial
31. Final Analysis of Randomized Phase III Study WJOG4007 Comparing Irinotecan (CPT-11) with weekly Paclitaxel (WPTX) in advanced Gastric Cancer (AGC) Refractory to Chemotherapy (CT) of Fluoropyrimidine Plus Platinum (FP)
32. Multicenter Feasibility Study of Combination Therapy with Fluorouracil, Leucovorin and Paclitaxel (FLTAX) for Peritoneal Disseminated Gastric Cancer with Massive Ascites or Inadequate Oral Intake
33. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours
34. Safety, Efficacy and Pharmacokinetics of Neratinib (HKI-272) in Japanese Patients with Advanced Solid Tumors: A Phase 1 Dose-escalation Study
35. 6107 POSTER Improved Overall Survival in the Patients With Metastatic Colorectal Cancer Associated With Ant-VEGF Antibody Drug and Anti-EGFR Antibody Drug Administration
36. Process-based distributed modeling approach for analysis of sediment dynamics in a river basin
37. Multicenter feasibility study of 5-FU, leucovorin, plus paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.
38. ChemInform Abstract: An Isomeric Series of Thiophene-Fused Tetracyanoquinodimethanes. Part 3. Crystal Structures of Charge-Transfer Complexes with TTF
39. Process-based distributed modeling approach for analysis of sediment dynamics in a river basin
40. Phase I Study of Docetaxel, Cisplatin and S-1 in Patients with Advanced Gastric Cancer
41. S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure
42. 1251 Evaluation of pharmacokinetics and safety profiles between S-1 granule and S-1 capsule in patients with solid tumors
43. 6624 Treatment of metastatic poorly differenciated neuroendocrine carcinoma (PDNEC) with irinotacan plus cisplatin
44. Tolerability and safety of oral neratinib (HKI-272) in Japanese patients with advanced solid tumors
45. Retrospective Analysis of S-1 Monotherapy in Patients with Metastatic Colorectal Cancer After Failure to Fluoropyrimidine and Irinotecan or to Fluoropyrimidine, Irinotecan and Oxaliplatin
46. Activity of S-1 in Advanced or Recurrent Gastric Cancer Patients after Failure of Prior Chemotherapy, Including Irinotecan + Cisplatin or Fluorouracil (Except S-1)
47. A Phase I Trial of 5-Fluorouracil with Cisplatin and Concurrent Standard-dose Radiotherapy in Japanese Patients with Stage II/III Esophageal Cancer
48. Irinotecan Plus Cisplatin Therapy and S-1 Plus Cisplatin Therapy for Advanced or Recurrent Gastric Cancer in a Single Institution
49. Impact of Baseline Sum of Longest Diameter in Target Lesions by RECIST on Survival of Patients with Metastatic Colorectal Cancer
50. Phase I/II study of S-1/LV plus oxaliplatin (SOL) for untreated metastatic colorectal cancer: Preliminary report of the phase I part
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.